Hyperlipidemia Drugs Market Report by Drug Type (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, and Others), End User (Hospitals, Clinics, and Others), and Region 2024-2032

Hyperlipidemia Drugs Market Report by Drug Type (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, and Others), End User (Hospitals, Clinics, and Others), and Region 2024-2032

Report Format: PDF+Excel | Report ID: SR112024A2685
Year End sale Buy Now

Market Overview:

The global hyperlipidemia drugs market size reached USD 22.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach USD 26.8 Billion by 2032, exhibiting a growth rate (CAGR) of 1.8% during 2024-2032.

Report Attribute 
Key Statistics
Base Year
2023
Forecast Years
2024-2032
Historical Years
2018-2023
Market Size in 2023
USD 22.7 Billion
Market Forecast in 2032
USD 26.8 Billion
Market Growth Rate (2024-2032) 1.8%


Hyperlipidemia, or high cholesterol, refers to a medical ailment characterized by high levels of fats in the bloodstream. It is the abnormal elevation of lipids and/or lipoprotein levels that can lead to stroke, peripheral vascular disease, atherosclerosis, diabetes, obesity, hypertension, and cardiovascular diseases. It is usually caused by genetic factors, unhealthy lifestyles and inadequate diet. Some of the commonly used hyperlipidemia drugs include statins, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors, bile acid sequestrants, fibric acid derivatives or fibrates and combination and miscellaneous antihyperlipidemic agents. These drugs reduce cholesterol production levels in the liver while further removing it from the bloodstream.

The increasing prevalence of hyperlipidemia across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to high levels of cholesterol and cardiovascular diseases, is also driving the market growth. In line with this, rising health consciousness among the masses and growing awareness regarding the available treatment alternatives for hypercholesterolemia is also favoring the market growth. Additionally, various technological advancements, such as the development of novel drug classes with enhanced efficacy, are acting as other growth-inducing factors. These drugs offer improved endothelial function and stability of atherosclerotic plaques and cause minimal inflammation and damage to the cells. Other factors, including the extensive research and development (R&D) activities in the field of biomedical sciences, along with overall improvements in the healthcare infrastructure across the globe, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hyperlipidemia drugs market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on drug type and end user.

Breakup by Drug Type:

  • Statins
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • PCSK9 Inhibitors
  • Others
     

Breakup by End User:

  • Hospitals
  • Clinics
  • Others
     

Breakup by Region:

Hyperlipidemia Drugs Market Report

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global hyperlipidemia drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:

  • Amgen Inc.
  • AstraZeneca PLC
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • Esperion Therapeutics Inc.
  • GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc)
  • Immuron Limited
  • Ionis Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi S.A.
     

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Report Coverage:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units Billion USD
Segment Coverage Drug Type, End User, Region
Region Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Amgen Inc., AstraZeneca PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc), Immuron Limited, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc. and Sanofi S.A.
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report

The global hyperlipidemia drugs market was valued at USD 22.7 Billion in 2023.

We expect the global hyperlipidemia drugs market to exhibit a CAGR of 1.8% during 2024-2032.

The rising demand for hyperlipidemia drugs to treat high cholesterol levels caused by genetic factors, unhealthy lifestyles, and inadequate diet is primarily driving the global hyperlipidemia drugs market.

The sudden outbreak of the COVID-19 pandemic has led to the increasing demand for hyperlipidemia drugs to provide safety from continuing lipid-lowering medication to the patients suffering from the coronavirus infection.

Based on the drug type, the global hyperlipidemia drugs market has been segmented into statins, bile acid sequestrants, cholesterol absorption inhibitors, PCSK9 inhibitors, and others. Currently, statins hold the majority of the total market share.

Based on the end user, the global hyperlipidemia drugs market can be divided into hospitals, clinics, and others. Among these, hospitals exhibit a clear dominance in the market.

On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin America, and Middle East and Africa, where Europe currently dominates the global market.

Some of the major players in the global hyperlipidemia drugs market include Amgen Inc., AstraZeneca PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc), Immuron Limited, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc., and Sanofi S.A.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Hyperlipidemia Drugs Market Report by Drug Type (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, and Others), End User (Hospitals, Clinics, and Others), and Region 2024-2032
Purchase Options Year End sale




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARATI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More
DEinternational Egypt

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

Read More
Gulf Excellent Group

I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand. I would also like to take this opportunity to inform you that we are greatly interested

Read More
FS Corporation Inc.

Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.

Read More
Egyptian Industrial Investment Group

The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.

Read More
Vishnu Chemicals

I’d like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer’s success. The entire team and company are incredibly thankful for your dedication. Once again, thank you

Read More
MOUNT EVEREST BREWERIES LIMITED

The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.

Read More
Borges Branded Foods

One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We’ve worked with them a couple of times and we will keep working with them in future projects.

Read More
Godrej Consumer Products Limited

We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.

Read More
ADC Therapeutics

The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.

Read More
Ivanti

The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.

Read More
Asiatic Electrical & Switchgear P. Ltd.

The report is excellent and has good amount of data and our team is extremely happy with the information provided.

Read More
Denka Co., Ltd.

Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.

Read More